Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Timing of REGEN-COV administration and progression to severe COVID-19
Kadowaki et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.07.002
Kadowaki et al., Timing of REGEN-COV administration and progression to severe COVID-19, Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.07.002
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 342 patients in Japan, showing significantly greater efficacy of casirivimab/imdevimab with earlier treatment. The proportion of patients progressing to severe COVID-19 increased daily from symptom onset and increased sharply from day 5.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
Kadowaki et al., 11 Jul 2022, retrospective, Japan, peer-reviewed, 5 authors, study period 19 July, 2021 - 30 September, 2021.
Contact: p5j44x0d@s.okayama-u.ac.jp.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: Journal of Infection and Chemotherapy xxx (xxxx) xxx Contents lists available at ScienceDirect Journal of Infection and Chemotherapy journal homepage: www.elsevier.com/locate/jic Original Article Timing of REGEN-COV administration and progression to severe COVID-19 Tomoka Kadowaki a, *, Sato Imajou b, Naomi Matsumoto a, Soshi Takao a, Takashi Yorifuji a a b Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan COVID-19 Infection Control Group, Okayama Prefecture Department of Health and Social Welfare, Okayama, Japan A R T I C L E I N F O A B S T R A C T Keywords: REGEN-COV COVID-19 Timing of administration Severe disease Epidemiology Introduction: Several clinical trials have demonstrated that REGEN-COV (casirivimab and imdevimab) decreases the risk of hospitalization and death among COVID-19 patients. However, these trials did not evaluate the optimal timing of its administration, and evidence is limited regarding the relationship between the timing of administration and progression to severe COVID-19 among patients who receive REGEN-COV in a real-world setting. We examined the association between the timing of REGEN-COV administration and progression to severe COVID-19 among patients who received REGEN-COV in Japan. Methods: We included a total of 342 COVID-19 patients (37 hospitals) who received REGEN-COV between July 19 and September 30, 2021. We calculated the difference between the date of symptom onset and the date of administration as an indicator of the timing of REGEN-COV administration and determined progression to severe COVID-19 after REGEN-COV administration. We conducted a logistic regression analysis, adjusting for potential confounders. Results: The proportion of cases progressing to severe COVID-19 increased daily from symptom onset and sharply increased from day 5 of onset. The early administration (days 0–4) decreased the risk of progression to severity compared with late administration (after day 5), with an adjusted odds ratio of 0.29 (95% confidence interval: 0.11–0.56). Conclusions: The early administration of REGEN-COV was associated with a decreased risk of progression to severe COVID-19 when the delta variant was dominant. The present epidemiological findings indicate that this monoclonal antibody therapy should be implemented very early in the clinical course probably even for emerging variants such as omicron BA.2.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit